A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4677-4680

  Saunders, M P ^a   Salisbury, A J ^a   O'Byrne, K J ^a   Souliotis, V L ^b   Varcoe, S M ^a   Talbot, D C ^a   Kyrtopoulos, S A ^b   Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b INSTITUTE OF BIOLOGY   (Greece)

Author keywords

AGT; Dacarbazine; DTIC; Melanoma; O6 methylguanine; Tamoxifen

Indexed keywords

6 O METHYLGUANINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; DACARBAZINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MALE; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031427217     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Safai B. In: Cancer - Principles and practice of oncology (DeVita VT, Hellman S, Rosenberg S, eds). J B Lippincott and Co, 4th ed, 1993, Ch 45 pp1636.
2. McClay EF, Mastrangelo MJ, Berd D, Bellet RE: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553-556, 1992.
3. Luikart SD, Kennealey GT, Kirkwood JM: Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164-168, 1984.
4. National Cancer Institute of Canada Melanoma group: Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. National Cancer Institute of Canada Melanoma Group. J Clin Oncol 2: 131-134, 1984.
5. Cocconi G, Bella M, Calabresi F et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen [see comments]. N Engl J Med 327: 516-523, 1992.
6. Rusthoven JJ, Quirt IC, Iscoe NA et al: Randomised, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14, vol 7: 2083-2090, 1996.
7. McClay EF, McClay ME: Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? [see comments]. J Clin Oncol 12: 617-626, 1994.
8. Fisher RI, Neifeld JP, Lippman ME: Oestrogen receptors in human malignant melanoma. Lancet 2: 337-339, 1976.
9. Philip PA, Souliotis VL, Harris AL et al: Methyl DNA adducts, DNA repair and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin Cancer Res 2: 303-310, 1996.
10. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
11. 6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines. Cancer Res 49: 4813-4817, 1989.
12. 6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70: 573-577, 1989.
13. Egyhazi S, Hansson J, Ringborg D: A study of the clinical response to dacarbazine in malignant melanoma in relation to the O6-methylguanine-DNA methyltransferase activity. Proc Am Assoc Cancer Res 34: 2119 (Abstr), 1993.
14. Schellens JH, Ma J, Planting AS et al: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73(12): 1569-1575, 1996.
15. Philip PA, Carmichael J, Tonkin K, Ganesan TA, Harris AL: A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Eur J Cancer 30A: 1027-1029, 1994.
16. 6-methylguanine. Cancer Res 49: 6997-7001, 1989.
17. 6-methylguanine in humans and rodents treated with dacarbazine. Carcinogenesis 17: 725-732, 1996.
18. 6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol 31: 240-246, 1992.